Investor interest in microbiome-based therapies perked up in early March with the completion of a £50 million Series B round for Microbiotica Ltd, one of Europe’s leading developers of microbiome-based therapeutics. The financing round was co-led by Flerie Invest of Sweden and Tencent of China, with participation from existing investors Cambridge Innovation Capital, IP Group, and Seventure Partners.
